Italia markets open in 7 hours 20 minutes

Soligenix, Inc. (0A6I.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,3599-0,0001 (-0,03%)
Alla chiusura: 03:04PM BST

Soligenix, Inc.

29 Emmons Drive
Suite B-10
Princeton, NJ 08540
United States
(609) 538-8200
https://www.soligenix.com

Settore/i
Settore
Impiegati a tempo pieno13

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Christopher J. Schaber Ph.D.Chairman of the Board of Directors, CEO & President625kN/D1966
Mr. Jonathan L. Guarino CPA, CGMASenior VP, CFO & Corporate Secretary309,4kN/D1973
Dr. Oreola Donini Ph.D.Senior VP & Chief Scientific Officer342,31kN/D1972
Dr. Richard C. Straube M.D., MSc.Senior VP & Chief Medical Officer212,2kN/D1952
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Soligenix, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.